SARS-CoV-2, Cardiovascular Diseases, and Noncoding RNAs: A Connected Triad

Coronavirus Disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is characterized by important respiratory impairments frequently associated with severe cardiovascular damages. Moreover, patients with pre-existing comorbidity for cardiovascular disease...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lucia Natarelli, Fabio Virgili, Christian Weber
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	SARS-CoV-2 COVID-19 cardiovascular diseases noncoding RNA Biology (General) QH301-705.5 Chemistry QD1-999
Acceso en línea:	https://doaj.org/article/4d5f9a6d82184db3a05875fea95664d9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4d5f9a6d82184db3a05875fea95664d9
record_format	dspace
spelling	oai:doaj.org-article:4d5f9a6d82184db3a05875fea95664d92021-11-25T17:54:40ZSARS-CoV-2, Cardiovascular Diseases, and Noncoding RNAs: A Connected Triad10.3390/ijms2222122431422-00671661-6596https://doaj.org/article/4d5f9a6d82184db3a05875fea95664d92021-11-01T00:00:00Zhttps://www.mdpi.com/1422-0067/22/22/12243https://doaj.org/toc/1661-6596https://doaj.org/toc/1422-0067Coronavirus Disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is characterized by important respiratory impairments frequently associated with severe cardiovascular damages. Moreover, patients with pre-existing comorbidity for cardiovascular diseases (CVD) often present a dramatic increase in inflammatory cytokines release, which increases the severity and adverse outcomes of the infection and, finally, mortality risk. Despite this evident association at the clinical level, the mechanisms linking CVD and COVID-19 are still blurry and unresolved. Noncoding RNAs (ncRNAs) are functional RNA molecules transcribed from DNA but usually not translated into proteins. They play an important role in the regulation of gene expression, either in relatively stable conditions or as a response to different stimuli, including viral infection, and are therefore considered a possible important target in the design of specific drugs. In this review, we introduce known associations and interactions between COVID-19 and CVD, discussing the role of ncRNAs within SARS-CoV-2 infection from the perspective of the development of efficient pharmacological tools to treat COVID-19 patients and taking into account the equally dramatic associated consequences, such as those affecting the cardiovascular system.Lucia NatarelliFabio VirgiliChristian WeberMDPI AGarticleSARS-CoV-2COVID-19cardiovascular diseasesnoncoding RNABiology (General)QH301-705.5ChemistryQD1-999ENInternational Journal of Molecular Sciences, Vol 22, Iss 12243, p 12243 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	SARS-CoV-2 COVID-19 cardiovascular diseases noncoding RNA Biology (General) QH301-705.5 Chemistry QD1-999
spellingShingle	SARS-CoV-2 COVID-19 cardiovascular diseases noncoding RNA Biology (General) QH301-705.5 Chemistry QD1-999 Lucia Natarelli Fabio Virgili Christian Weber SARS-CoV-2, Cardiovascular Diseases, and Noncoding RNAs: A Connected Triad
description	Coronavirus Disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is characterized by important respiratory impairments frequently associated with severe cardiovascular damages. Moreover, patients with pre-existing comorbidity for cardiovascular diseases (CVD) often present a dramatic increase in inflammatory cytokines release, which increases the severity and adverse outcomes of the infection and, finally, mortality risk. Despite this evident association at the clinical level, the mechanisms linking CVD and COVID-19 are still blurry and unresolved. Noncoding RNAs (ncRNAs) are functional RNA molecules transcribed from DNA but usually not translated into proteins. They play an important role in the regulation of gene expression, either in relatively stable conditions or as a response to different stimuli, including viral infection, and are therefore considered a possible important target in the design of specific drugs. In this review, we introduce known associations and interactions between COVID-19 and CVD, discussing the role of ncRNAs within SARS-CoV-2 infection from the perspective of the development of efficient pharmacological tools to treat COVID-19 patients and taking into account the equally dramatic associated consequences, such as those affecting the cardiovascular system.
format	article
author	Lucia Natarelli Fabio Virgili Christian Weber
author_facet	Lucia Natarelli Fabio Virgili Christian Weber
author_sort	Lucia Natarelli
title	SARS-CoV-2, Cardiovascular Diseases, and Noncoding RNAs: A Connected Triad
title_short	SARS-CoV-2, Cardiovascular Diseases, and Noncoding RNAs: A Connected Triad
title_full	SARS-CoV-2, Cardiovascular Diseases, and Noncoding RNAs: A Connected Triad
title_fullStr	SARS-CoV-2, Cardiovascular Diseases, and Noncoding RNAs: A Connected Triad
title_full_unstemmed	SARS-CoV-2, Cardiovascular Diseases, and Noncoding RNAs: A Connected Triad
title_sort	sars-cov-2, cardiovascular diseases, and noncoding rnas: a connected triad
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/4d5f9a6d82184db3a05875fea95664d9
work_keys_str_mv	AT lucianatarelli sarscov2cardiovasculardiseasesandnoncodingrnasaconnectedtriad AT fabiovirgili sarscov2cardiovasculardiseasesandnoncodingrnasaconnectedtriad AT christianweber sarscov2cardiovasculardiseasesandnoncodingrnasaconnectedtriad
_version_	1718411859820806144

SARS-CoV-2, Cardiovascular Diseases, and Noncoding RNAs: A Connected Triad

Ejemplares similares